Summary
GlobalData, the industry analysis specialist, has released a new report on the Pharmaceutical and Healthcare industry, "Influenza Vaccines-Pipeline Analysis and Market Forecasts to 2016" is an essential source of information and analysis on the global influenza vaccines market. The report identifies the key trends shaping and driving the global influenza vaccines market, a key segment within the pharma industry. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global influenza vaccines sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData's team of industry experts.

Scope
The scope of the report includes:
-Annualized global influenza vaccines market revenues data from 2000 to 2009, forecast forward for 7 years to 2016.
-Geographic markets covered in this report include the US, the UK, Italy, Spain, Germany, France, and Japan.
-Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends.
-Analysis of the current and future market competition in the global influenza vaccines market. Key market players covered include Sanofi-aventis (Sanofi Pasteur), Novartis, GSK, CSL Limited and MedImmune.
-Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
-Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with influenza vaccines.

Reasons to buy
The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
-Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
-Develop business strategies by understanding the trends shaping and driving the global influenza vaccines market.
-Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global influenza vaccines market in future.
-Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
-Identify emerging players with potentially strong product portfolio and create effective   counter-strategies to gain competitive advantage.
-Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
-What's the next big thing in the global influenza vaccines market landscape? -Identify, understand and capitalize.

Table of Contents
1 Table of contents 3
1.1 List of Tables 5
1.2 List of Figures 5
2 Influenza Vaccines: Market Characterization 6
2.1 Overview 6
2.2 Influenza Vaccines Market Size 6
2.3 Influenza Vaccines Market Forecast and CAGR 6
2.4 Drivers and Barriers for Influenza Vaccines Market 8
2.4.1 Drivers for Influenza Vaccines Market 8
2.4.2 Barriers for Influenza Vaccines Market 8
2.5 Opportunity and Unmet Need 9
2.6 Key Takeaway 10
3 Influenza Vaccines Market: Competitive Assessment 11
3.1 Overview 11
3.2 Strategic Competitor Assessment 11
3.3 Product Profile for the Major Marketed Vaccines in Influenza Market 11
3.3.1 Fluzone 11
3.3.2 Fluarix 12
3.3.3 Fluvirin 13
3.3.4 FluLaval 14
3.4 Major Marketed Products Comparison in Influenza Vaccines Market 15
3.5 Key Takeaway 15
4 Influenza Vaccines Market: Pipeline Assessment 16
4.1 Overview 16
4.2 Strategic Pipeline Assessment 16
4.2.1 Technology Trends Analytical Framework 16
4.3 Influenza Vaccines-Promising Vaccines under Clinical Development 17
4.4 Molecule Profile for Promising Vaccines under Clinical Development 17
4.4.1 Optaflu 17
4.4.2 Intanza/IDflu 18
4.4.3 GSK2186877A 18
4.5 Influenza Vaccines Market-Clinical Pipeline by Vaccine Class 19
4.6 Influenza Vaccines Pipeline-Pipeline by Clinical Phases of Development 20
4.6.1 Influenza Vaccines-Phase III Clinical Pipeline 20
4.6.2 Influenza Vaccines-Phase III Clinical Pipeline 21
4.6.3 Influenza Vaccines-Phase II Clinical Pipeline 21
4.6.4 Influenza Vaccines-Phase I Clinical Pipeline 22
4.6.5 Influenza Vaccines-Preclinical Pipeline 23
4.6.6 Influenza Vaccines-Discovery Pipeline 24
4.7 Discontinued/Suspended Vaccines for Influenza 24
4.8 Key Takeaway 24
5 Global Influenza Vaccines Market: Implications for Future Market Competition 25
6 Global Influenza Vaccines Market: Future Players in Influenza Vaccines Market 26
6.1 Introduction 26
6.2 Novartis 26
6.2.1 Company Overview 26
6.2.2 Business Description 27
6.2.3 Infectious Diseases Vaccines Pipeline 27
6.2.4 Influenza Vaccines Pipeline 28
6.3 GlaxoSmithKline 28
6.3.1 Company Overview 28
6.3.2 Business Description 28
6.3.3 Infectious Diseases Vaccines Pipeline 29
6.3.4 Influenza Vaccines Pipeline 29
6.4 Sanofi-aventis 29
6.4.1 Company Overview 29
6.4.2 Business Description 30
6.4.3 Infectious Diseases Vaccines Pipeline 30
6.4.4 Influenza Vaccines Pipeline 30
6.5 CSL Limited 31
6.5.1 Company Overview 31
6.5.2 Business Description 31
6.5.3 Infectious Diseases Vaccines Pipeline 31
6.5.4 Influenza Vaccines Pipeline 32
6.6 MedImmune 32
6.6.1 Company Overview 32
6.6.2 Business Description 32
6.6.3 Infectious Diseases Vaccines Pipeline 33
6.6.4 Influenza Vaccines Pipeline 33
7 Global Influenza Vaccines Market: Appendix 34
7.1 Market Definitions 34
7.2 Abbreviations 34
7.3 Research Methodology 34
7.3.1 Coverage 35
7.3.2 Secondary Research 35
7.3.3 Forecasting 35
7.3.4 Primary Research 37
7.3.5 Expert Panel Validation 38
7.4 Contact Us 38
7.5 Disclaimer 38
7.6 Sources 38

List of Tables
1.1 List of Tables
Table 1: Global Influenza Vaccines Market, Revenues ($bn), 2007-2009 7
Table 2: Global Influenza Vaccines Market, Revenues ($bn), 2010-2016 7
Table 3: Major Marketed Products Comparison in Influenza Vaccines Market, 2010 15
Table 4: Influenza Vaccines-Phase III Clinical Pipeline, 2010 20
Table 5: Influenza Vaccines-Phase III Clinical Pipeline, 2010 21
Table 6: Influenza Vaccines-Phase II Clinical Pipeline, 2010 21
Table 7: Influenza Vaccines-Phase I Clinical Pipeline, 2010 22
Table 8: Influenza Vaccines-Preclinical Pipeline, 2010 23
Table 9: Influenza Vaccines-Discovery Pipeline, 2010 24
Table 10: List of Discontinued Vaccines for Influenza, 2010 24
Table 11: Novartis, Infectious Diseases Vaccines Pipeline, 2010 27
Table 12: Novartis, Influenza Vaccines Pipeline, 2010 28
Table 13: GlaxoSmithKline, Infectious Diseases Vaccines Pipeline, 2010 29
Table 14: GlaxoSmithKline, Influenza Vaccines Pipeline, 2010 29
Table 15: Sanofi-aventis, Infectious Diseases Vaccines Pipeline, 2010 30
Table 16: Sanofi-aventis, Influenza Vaccines Pipeline, 2010 30
Table 17: CSL Limited, Infectious Diseases Vaccines Pipeline, 2010 31
Table 18: CSL Limited, Influenza Vaccines Pipeline, 2010 32
Table 19: MedImmune, Infectious Diseases Vaccines Pipeline, 2010 33
Table 20: MedImmune, Influenza Vaccines Pipeline, 2010 33

List of Figures
1.2 List of Figures
Figure 1: Global Influenza Vaccines Market, Revenues ($bn), 2007-2016 7
Figure 2: Opportunity and Unmet Need in the Influenza Vaccines Market, 2010 10
Figure 3: Strategic Competitor Assessment of the Influenza Vaccines Market, 2010 11
Figure 4: Technology Trends Analytic Framework-Influenza Vaccines Market, 2010 16
Figure 5: Technology Trends Analytic Framework-Description-Influenza Vaccines Market, 2010 17
Figure 6: Influenza Vaccines Market-Clinical Pipeline by Class of Vaccine, 2010 19
Figure 7: Influenza Vaccines Pipeline by Phase of Clinical Development, 2010 20
Figure 8: Implications For Future Market Competition in the Influenza Vaccines Market, 2010 25
Figure 9: Influenza Vaccines Market-Clinical Pipeline by Company, 2010 26
Figure 10:  GlobalData Methodology 34
Figure 11:  GlobalData  Market Forecasting Model 37